India coach Ravi Shastri hailed his team's eight-wicket win over Australia on Tuesday (29) as one of the great comebacks of all time, praising their character after a crushing loss in the first Test last week.
Despite missing superstar Virat Kohli, the Indians outplayed the hosts in Melbourne to silence their critics after being dismissed for 36 in Adelaide on their way to an eight-wicket defeat.
"I think this will go down in the annals of Indian cricket, world cricket, as one of the great comebacks in the history of the game," said Shastri after they levelled the series 1-1.
"To be rolled over for 36, then three days later to get up and be ready to punch was outstanding.
"I think the boys deserve all the credit for showing real character."
India's win was built on a first-innings century by stand-in captain Ajinkya Rahane on their way to 326 in reply to Australia's 195, with young debutant Shubman Gill also excelling with the bat.
But their bowling attack, minus Umesh Yadav who pulled out injured on Monday, also delivered, with a standout performance from Mohammed Siraj, another on debut.
Shastri said both Siraj and Gill had big futures ahead.
"These two debutants showed a maturity and flair and discipline and it was great to see," he said.
"Today Siraj, his effort was outstanding. He might not have the numbers to show for it, but the discipline and the ability to bowl long spells was outstanding.
"More than anything, they have shown great character."
Kohli, watching at home in India ahead of his wife giving birth to their first child, was equally impressed by what he saw.
"What a win this is, absolutely amazing effort by the whole team," he tweeted.
"Couldn't be happier for the boys and specially Jinks (Rahane) who led the team to victory amazingly."
- 'Shrewd leader' Rahane -
Shastri paid particular tribute to Rahane, who in contrast to Kohli is a less flamboyant captain, but equally effective.
"He is a very shrewd leader, he has a good understanding of the game, he's a good reader of the game," he said.
"And I thought his calm composure out there in the middle, it helped the debutants and I think it helped the bowlers as well. It was a calming influence."
Despite winning, India head into the third Test next week with selection dilemmas.
Shastri said they were monitoring Yadav but would be sticking with their five-bowler strategy, having included allrounder Ravindra Jadeja for Melbourne.
They also have key batsman Rohit Sharma out of mandatory quarantine and ready to join the team after recovering from a hamstring injury.
"We will stick to five bowlers," Shastri said.
"On Rohit, he joins the team tomorrow so we will have a chat with him to see where he is placed physically, because he's been in quarantine for the last couple of weeks.
"We also need to see how he feels before we make the call."
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.